Zimmer Biomet Unveils AI, Robotics, and a Hollywood Heavyweight

WARSAW, Ind. – February 25, 2026 – Medical technology leader Zimmer Biomet is poised for a commanding presence at the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting, signaling a major push into the next generation of musculoskeletal care. The company is set to unveil a trove of new clinical data and a suite of advanced technologies, headlined by a main-stage appearance from its high-profile Chief Movement Officer, Arnold Schwarzenegger.

The announcements paint a picture of a company aggressively pursuing a future where orthopedic surgery is more precise, patient recovery is data-driven, and care extends far beyond the hospital walls. This strategy hinges on a portfolio of innovations the company has dubbed its “Magnificent Seven,” a collection of robotic, digital, and implant technologies designed to work in concert.

“Our presence at the AAOS Annual Meeting will highlight Zimmer Biomet's leadership in orthopedic implants coupled with the robotic and digital technologies that collect data before, during and after surgery to provide insights that help surgeons understand the potential impact of surgical decisions on patient outcomes,” said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet.

The Robotic and Digital Revolution in Orthopedics

At the core of Zimmer Biomet’s showcase is a formidable lineup of technologies aimed at revolutionizing the operating room. The company is betting on a multi-faceted approach to robotics, offering surgeons a spectrum of options from large-console systems to compact, handheld devices.

Leading the charge is the newly enhanced ROSA® Knee with OptimiZe™, which received FDA clearance in late 2025. This system builds upon the established ROSA platform by incorporating intelligent surgical planning and an automated kinematic alignment feature. The goal is to resurface the knee with a high degree of accuracy, aiming to restore its natural, pre-arthritic position and reduce variability between surgeons.

For healthcare settings where space and capital are at a premium, the company is highlighting the TMINI® Miniature Robotic System. This handheld, CT-based robotic tool, developed in partnership with THINK Surgical, offers the precision of robotics in a wireless, ergonomic package. Its compact size makes it particularly well-suited for the rapidly growing number of orthopedic procedures performed in ambulatory surgery centers (ASCs).

Further solidifying its robotics pipeline, Zimmer Biomet will also feature the Monogram Technologies TKA System, a CT-based, semi-autonomous robotic technology acquired by the company in October 2025. With a fully autonomous version already in clinical trials, this platform represents a significant step toward the future of automated surgical procedures, promising enhanced safety and efficiency.

Perhaps the most transformative innovation is the Persona IQ®, the world's first and only FDA-cleared “smart knee” implant. The device embeds sensors directly into the knee implant to capture real-time, objective patient data on range of motion, step count, and walking speed post-surgery. This information is transmitted to the surgeon and patient via a digital platform, enabling a new paradigm of remote monitoring and personalized recovery.

From Terminator to Motivator: Schwarzenegger’s Health Crusade

Adding significant star power and a unique strategic dimension to the company's efforts is Arnold Schwarzenegger, who will take the stage as the conference's Presidential Guest Speaker. Appointed as Zimmer Biomet's Chief Movement Officer in 2024, Schwarzenegger’s role is far more than a simple celebrity endorsement. He is tasked with a mission: to leverage his global platform to advocate for mobility, joint health, and active lifestyles.

On March 5, he will join CEO Ivan Tornos and AAOS President Dr. Ned Amendola for a discussion on sustaining peak performance and thriving under pressure—themes that resonate deeply with both his own career and the high-stakes world of orthopedic surgery. The partnership is a strategic move to bridge the gap between complex medical technology and the public's desire for a healthy, active life. By framing joint replacement not as an end point but as a new beginning for movement, the collaboration aims to empower patients and destigmatize orthopedic procedures.

Data as the New Standard of Care

Beyond the hardware, Zimmer Biomet is emphasizing the power of data to improve patient outcomes. The company will present several new studies at AAOS, many of which leverage the unique data-gathering capabilities of its Persona IQ smart knee. These presentations aim to establish a direct link between post-operative movement patterns and clinical results.

One study explores the relationship between an early decline in a patient’s gait, as measured by the smart implant, and the potential onset of periprosthetic joint infections. Another investigates how qualified step counts after surgery correlate with the risk of venous thromboembolisms, or blood clots. This research highlights a shift toward proactive, predictive care, where objective data can alert care teams to potential complications before they become critical. Additional data will be presented on the long-term safety and efficacy of the Oxford® Cementless Partial Knee, which celebrates 50 years of clinical heritage and boasts excellent survivorship rates in global joint registries.

A Strategy for Care Beyond the Hospital Walls

The entire portfolio of innovations points to a broader strategy focused on the accelerating shift of orthopedic procedures from traditional hospitals to more efficient Ambulatory Surgery Centers. The company's ZBX™ Ambulatory Surgery Center Solutions offering provides a comprehensive framework to help surgeons establish and operate these outpatient facilities. Technologies like the compact TMINI robot and the data-monitoring capabilities of Persona IQ are tailor-made for the ASC model, which prioritizes efficiency, cost-effectiveness, and a better patient experience.

This strategic pivot is further bolstered by the recent acquisition of Paragon 28, a specialist in the foot and ankle market—one of the fastest-growing segments in orthopedics. The integration of Paragon 28’s portfolio not only diversifies Zimmer Biomet's offerings but also strengthens its ability to serve the ASC market with a comprehensive suite of solutions for extremities. By combining advanced robotics, data-driven smart implants, and a focus on outpatient efficiency, Zimmer Biomet is not just showcasing new products; it is presenting a cohesive vision for the future of orthopedic care.